First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Clinical trial NCT05832827 · RECRUITING
Trial details
- NCT number
- NCT05832827
- Sponsor
- National Cancer Center, Japan
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-04
- Primary completion
- 2025-12-31
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.